Meta-analysis associates emerging lesions after lutetium-177 therapy with worse overall survival in mCRPC

This systematic review and meta-analysis synthesized data regarding interim post-treatment SPECT/CT imaging following lutetium-177 (177Lu)-PSMA therapy. The review focused on patients with metastatic castration-resistant prostate cancer, encompassing a total sample size of 648 patients. Primary outcomes included overall survival and PSA-progression-free survival. The specific setting was not reported in the source documentation provided.

The analysis clearly identified that emerging new lesions were associated with worse overall survival. The reported effect size indicated a hazard ratio of 2.78, with a 95% confidence interval of 1.91–4.06. No data were reported regarding PSA-progression-free survival outcomes in the provided summary.

The authors acknowledge that standardization and prospective validation are needed to integrate it into clinical practice. Follow-up duration was not reported in the source material. Safety data, including adverse events and discontinuations, were not reported. Funding or conflicts were not reported. The lack of reported safety data limits the assessment of tolerability.

Clinicians should interpret these findings cautiously given the observational nature of the underlying data synthesis. Prospective validation is currently required to establish utility. Current evidence does not support definitive causal claims regarding lesion emergence.

Further studies are needed to confirm these associations in future research. Integration into clinical practice requires standardization and prospective validation.